Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide.
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …

Objective To harness the frontline therapy in advanced penile squamous cell carcinoma
(PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is …

Background The evaluation of the proportional hazards (PH) assumption in survival analysis
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …

Ten years ago, somatic mutations in EGFR were identified in patients with non-small-cell
lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Abstract KRAS (Kirsten Rat Sarcoma) is the most common oncogenic mutation detected in
patients with non-small cell lung cancer (NSCLC). However, the role of KRAS as either a …

The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for
almost 80%–85% of all lung cancer cases. Unfortunately, more than half of the patients will …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …